Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Dimopoulos, MA; San-Miguel, J; Belch, A; White, D; Benboubker, L; Cook, G; Leiba, M; Morton, J; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Kaufman, JL; Sutherland, HJ; Lalancette, M; Magen, H; Iida, S; Kim, JS; Prince, HM; Cochrane, T; Oriol, A; Bahlis,

Dimopoulos, MA (reprint author), Univ Athens, Athens, Greece.

HAEMATOLOGICA, 2018; 103 (12): 2088

Abstract

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alo......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索